EGFR and non-small cell lung carcinoma: - Open-label multicenter Phase I trial evaluating combination of gefitinib and durvalumab in patients with EGFR-mutant and EGFR TKI-naïve NSCLC- No significant improvement in PFS or ORR compared with gefitinib monotherapy previously reported in similar patient populations.- Gefitinib-naïve patients: ORR=63.6%; DoR=9.2 months; PFS=10.1 months- Gefitinib-pretreated patients: ORR=70.0%; DoR=12.6 months; PFS=12.0 months